Memphasys accelerates commercial approval for sperm-separation device
![](https://www.sharecafe.com.au/wp-content/uploads/2024/01/fnn-447963.jpg)
Despite innovative technology, Memphasys (ASX:MEM) has been swimming against the tide in recent times. But with the company poised to bank $4.23 million in a capital raising and having signed expanded distribution agreements, wary investors can expect better times as the company shifts from a research and development focus to commercialisation.
Read More